Award

Ask AI about this notice

Summarise, research or assess it with AI

View Markdown

Share this notice

Send this contract to a colleague

NHS National Generic Pharmaceuticals Transition 2021_1

The NHS Commissioning Board (operating under the name of NHS England)

This public procurement record has 1 release in its history.

Award

29 Apr 2021 at 13:43

Award Notice
Summary of the contracting process

The NHS Commissioning Board, operating as NHS England, initiated a tender titled "NHS National Generic Pharmaceuticals Transition 2021_1", primarily focused on pharmaceutical products under the goods category. The procurement process is currently in the awarded stage, following an open procedure and was executed in the UK. The framework agreement has a total maximum duration of 29 months, with provisions for call-offs commencing from April 15, 2021, up to June 30, 2022, depending on the specific regional lots. Key aspects include potential extensions at the buyer's discretion and an emphasis on various award criteria beyond just price.

This tender presents significant growth opportunities for businesses within the pharmaceutical sector, particularly for SMEs that can supply both transition and various medicinal products. Companies with capabilities in manufacturing, distributing, or providing pharmaceutical products are well-positioned to compete. The active status of multiple lots across various UK regions means there are numerous avenues for participation, making it an attractive prospect for both local and larger-scale pharmaceutical firms aiming to expand their market presence.

How relevant is this notice?

Notice Information

Notice Title

NHS National Generic Pharmaceuticals Transition 2021_1

Notice Description

Transition and 33 % products:CESW 15 April 2021 to 30 September 2021 (5.5 months);LSNE 15 April 2021 to 28 February 2022 (10.5 months);NWLN 15 April 2021 to 30 June 2022 (14.5 months);100 % Products (All Regions): 15 April 2021 to 28 February 2022 (10.5 months).The total maximum duration of the framework agreement to be no more than 29 months (14.5 months plus options to extend (at the Authority's sole discretion) for up to a further 14.5 months).

Lot Information

Transition 2021_1 - 100% Products (All regions)

NHS National Pharmaceuticals Transition 2021_1 Offer reference number: CM/PHG/20/5629 Period of framework agreement: the total maximum duration of the framework agreement to be no more than 29 months (14.5 months plus options to extend (at the Authority's sole discretion) for up to a further 14.5 months) Potential Periods of call-offs under the framework agreement Transition and 33 % Products:CESW 15 April 2021 to 30 September 2021 (5.5 months);LSNE 15 April 2021 to 28 February 2022 (10.5 months);NWLN 15 April 2021 to 30 June 2022 (14.5 months);100 % Products (All Regions): 15 April 2021 to 28 February 2022 (10.5 months). Additional information: Price is not the only award criterion and all criteria are stated only in the procurementdocuments

Options: Options to extend (at the Authority's sole discretion) for up to a further 10.5 months.

Transition 2021_1 - CESW region (Transition & 33% products)

NHS National Pharmaceuticals Transition 2021_1 Offer reference number: CM/PHG/20/5629 Period of framework agreement: the total maximum duration of the framework agreement to be no more than 29 months (14.5 months plus options to extend (at the Authority's sole discretion) for up to a further 14.5 months) Potential Periods of call-offs under the framework agreement Transition and 33 % Products:CESW 15 April 2021 to 30 September 2021 (5.5 months);LSNE 15 April 2021 to 28 February 2022 (10.5 months);NWLN 15 April 2021 to 30 June 2022 (14.5 months);100 % Products (All Regions): 15 April 2021 to 28 February 2022 (10.5 months) Additional information: Price is not the only award criterion and all criteria are stated only in the procurementdocuments

Options: Options to extend (at the Authority's sole discretion) for up to a further 5.5 months.

Transition 2021_1 - LSNE region (Transition & 33% products)

NHS National Pharmaceuticals Transition 2021_1 Offer reference number: CM/PHG/20/5629 Period of framework agreement: the total maximum duration of the framework agreement to be no more than 29 months (14.5 months plus options to extend (at the Authority's sole discretion) for up to a further 14.5 months) Potential Periods of call-offs under the framework agreement Transition and 33 % Products:CESW 15 April 2021 to 30 September 2021 (5.5 months);LSNE 15 April 2021 to 28 February 2022 (10.5 months);NWLN 15 April 2021 to 30 June 2022 (14.5 months);100 % Products (All Regions): 15 April 2021 to 28 February 2022 (10.5 months)

Options: Options to extend (at the Authority's sole discretion) for up to a further 10.5 months.

Transition 2021_1 - NWLN region (Transition & 33% products)

NHS National Pharmaceuticals Transition 2021_1 Offer reference number: CM/PHG/20/5629 Period of framework agreement: the total maximum duration of the framework agreement to be no more than 29 months (14.5 months plus options to extend (at the Authority's sole discretion) for up to a further 14.5 months) Potential Periods of call-offs under the framework agreement Transition and 33 % Products:CESW 15 April 2021 to 30 September 2021 (5.5 months);LSNE 15 April 2021 to 28 February 2022 (10.5 months);NWLN 15 April 2021 to 30 June 2022 (14.5 months);100 % Products (All Regions): 15 April 2021 to 28 February 2022 (10.5 months). Additional information: Price is not the only award criterion and all criteria are stated only in the procurementdocuments

Options: Options to extend (at the Authority's sole discretion) for up to a further 14.5 months.

Notice Details

Publication & Lifecycle

Open Contracting ID
ocds-h6vhtk-02aba8
Publication Source
Find A Tender Service
Latest Notice
https://www.find-tender.service.gov.uk/Notice/009271-2021
Current Stage
Award
All Stages
Award

Procurement Classification

Notice Type
Award Notice
Procurement Type
Framework
Procurement Category
Goods
Procurement Method
Open
Procurement Method Details
Open procedure
Tender Suitability
Not specified
Awardee Scale
Large, SME

Common Procurement Vocabulary (CPV)

CPV Divisions

33 - Medical equipments, pharmaceuticals and personal care products

CPV Codes

33600000 - Pharmaceutical products

33690000 - Various medicinal products

Notice Value(s)

Tender Value
Not specified
Lots Value
Not specified
Awards Value
Not specified
Contracts Value
£1

Notice Dates

Publication Date
29 Apr 20215 years ago
Submission Deadline
Not specified
Future Notice Date
Not specified
Award Date
17 Mar 20215 years ago
Contract Period
Not specified - Not specified
Recurrence
Not specified

Notice Status

Tender Status
Complete
Lots Status
Cancelled
Awards Status
Active
Contracts Status
Active

Buyer & Supplier

Contracting Authority (Buyer)

Main Buyer
The NHS Commissioning Board (operating under the name of NHS England)
Contact Name
Available with D3 Tenders Premium →
Contact Email
Available with D3 Tenders Premium →
Contact Phone
Available with D3 Tenders Premium →

Buyer Location

Locality
RUNCORN
Postcode
WA7 2ES
Postcode Area
Warrington
Country
England
Major Region (ITL 1)
TLD North West (England)
Basic Region (ITL 2)
TLD7 Merseyside
Small Region (ITL 3)
TLD71 East Merseyside
Delivery Location
Not specified
Local Authority
Halton
Electoral Ward
Halton Lea
Westminster Constituency
Runcorn and Helsby

Supplier Information

Number of Suppliers
20
Supplier Names

Accord-UK Ltd

Amarox Limited

Ascend Laboratories UK Ltd

Aspen Pharma Ireland Limited

Aspire Pharma Limited

Aventis Pharma ltd t/a Sanofi

Brown and Burk UK Ltd

Day Lewis Medical Ltd

Dr.Reddy's Laboratories (UK) Limited

Kent Pharma Ltd

Martindale Pharma

Morningside Pharmaeuticals

Panpharma UK Limited

Pfizer Ltd

Ranbaxy UK

Selective Supplies Ltd.

Teva UK Limited

Thornton and Ross Ltd

Tillomed Laboratories ltd

medac Pharma LLP

Further Information

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

JSON Markdown

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

Loading OCDS record...